Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Janjigian, Yelena Y.; Al-Batran, Salah-Eddin; Wainberg, Zev A.; Van Cutsem, Eric; Molena, Daniela; Muro, Kei; Hyung, Woo Jin; Wyrwicz, Lucjan S.; Oh, Do-Youn; Omori, Takeshi; Moehler, Markus; Garrido, Marcelo; Oliveira, Sulene C. S.; Liberman, Moishe; Castro Oliden, Victor; Bilici, Mehmet; Kurland, John F.; Xynos, Ioannis; Mann, Helen; Tabernero, Josep

doi:10.1200/jco.2024.42.3_suppl.lba246

Makale Uluslararası 2024

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan S. Wyrwicz, Do-Youn Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sulene C. S. Oliveira, Moishe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero

JOURNAL OF CLINICAL ONCOLOGY Cilt 42 · Sayı 3_SUPPL · ss. 245–246 · 01.01.2024

DOI ile aç

Atıf için künye

Janjigian, Y. Y., Al-Batran, S., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., Hyung, W. J., Wyrwicz, L. S., Oh, D., Omori, T., Moehler, M., Garrido, M., Oliveira, S. C. S., Liberman, M., Castro Oliden, V., Bilici, M., Kurland, J. F., Xynos, I., Mann, H., & Tabernero, J. (2024). Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study. JOURNAL OF CLINICAL ONCOLOGY, 42(3_SUPPL), 245–246. https://doi.org/10.1200/jco.2024.42.3_suppl.lba246

BibTeX

@article{janjigian2024-228375,
  author = {Janjigian, Yelena Y. and Al-Batran, Salah-Eddin and Wainberg, Zev A. and Van Cutsem, Eric and Molena, Daniela and Muro, Kei and Hyung, Woo Jin and Wyrwicz, Lucjan S. and Oh, Do-Youn and Omori, Takeshi and Moehler, Markus and Garrido, Marcelo and Oliveira, Sulene C. S. and Liberman, Moishe and Castro Oliden, Victor and Bilici, Mehmet and Kurland, John F. and Xynos, Ioannis and Mann, Helen and Tabernero, Josep},
  title = {Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study},
  journal = {JOURNAL OF CLINICAL ONCOLOGY},
  year = {2024},
  volume = {42},
  number = {3_SUPPL},
  pages = {245--246},
  issn = {0732-183X},
  doi = {10.1200/jco.2024.42.3_suppl.lba246},
  url = {https://akademik.atauni.edu.tr/yayinlar/228375-pathological-complete-response-pcr-to-5-fluorouracil-leucovorin-oxaliplatin-and}
}